We attended the Conference on Retroviruses and Opportunistic Infections.”
We attended CROI, the traditional Conference on Retroviruses and Opportunistic Infections, held this year in Denver, USA. We participated in the presentation of results from the PURPOSE 2 and ARTISTRY studies, among other exchange activities with colleagues from around the world. We are proud to be part of these cutting-edge research and innovation initiatives. Follow-up from the PURPOSE study confirms the extraordinary efficacy of a medication administered subcutaneously every six months to prevent HIV acquisition in at-risk individuals. The ARTISTRY study—published in The Lancet in conjunction with its presentation at this conference—shows that a simplified one-tablet-a-day regimen facilitates treatment for people who had been on complex regimens due to long-term infection (over 25 years) and exposure to multiple treatments. These long-acting drugs promise to revolutionize HIV prevention and treatment.
